TY - JOUR
T1 - The receptor expression pattern in ductal carcinoma in situ predicts recurrence
AU - Kepple, Julie
AU - Henry-Tillman, Ronda S.
AU - Klimberg, V. Suzanne
AU - Layeeque, Rakshanda
AU - Siegel, Eric
AU - Westbrook, Kent
AU - Korourian, Soheila
N1 - Funding Information:
Supported by the Susan G. Komen Breast Cancer Clinical Fellowship (J. K. and R. L.) and the Virginia Clinton Kelley/Fashion Footwear Association of New York Breast Cancer Research Fellowship (J. K. and R. L.).
PY - 2006/7
Y1 - 2006/7
N2 - Background: The treatment of ductal carcinoma in situ (DCIS) is based on size and pathologic morphology. We hypothesized that as with invasive breast cancer, receptor expression in DCIS is important for predicting recurrence. Methods: Retrospective review from 1990 through 2002 identified 94 DCIS patients who had documented estrogen receptor (ER), progesterone receptor (PR), p53, Her-2/neu (HER), tumor characteristics, type of surgery, use of radiation or tamoxifen, and site of recurrence. Results: Median age and tumor size was 57.5 years and 2.0 cm, respectively. Median follow-up was 4 years. Overall recurrence rate was 6%. The ER-positive/PR-negative/HER-positive receptor pattern represented 50% (3 of 6) of total recurrences (P = .01). The length of disease-free-survival in the ER-positive/PR-negative/HER-positive receptor pattern was significantly shorter than in the rest of the patients (P = .0011). Comments: Receptor expression may be important in DCIS for predicting recurrence. HER positivity, even with ER positivity, is significantly associated with a higher risk of recurrence.
AB - Background: The treatment of ductal carcinoma in situ (DCIS) is based on size and pathologic morphology. We hypothesized that as with invasive breast cancer, receptor expression in DCIS is important for predicting recurrence. Methods: Retrospective review from 1990 through 2002 identified 94 DCIS patients who had documented estrogen receptor (ER), progesterone receptor (PR), p53, Her-2/neu (HER), tumor characteristics, type of surgery, use of radiation or tamoxifen, and site of recurrence. Results: Median age and tumor size was 57.5 years and 2.0 cm, respectively. Median follow-up was 4 years. Overall recurrence rate was 6%. The ER-positive/PR-negative/HER-positive receptor pattern represented 50% (3 of 6) of total recurrences (P = .01). The length of disease-free-survival in the ER-positive/PR-negative/HER-positive receptor pattern was significantly shorter than in the rest of the patients (P = .0011). Comments: Receptor expression may be important in DCIS for predicting recurrence. HER positivity, even with ER positivity, is significantly associated with a higher risk of recurrence.
KW - Breast cancer
KW - Ductal carcinoma in situ
KW - Estrogen receptor
KW - HER 2 neu receptor
KW - Recurrence
KW - Tamoxifen
UR - http://www.scopus.com/inward/record.url?scp=33745044215&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33745044215&partnerID=8YFLogxK
U2 - 10.1016/j.amjsurg.2006.04.002
DO - 10.1016/j.amjsurg.2006.04.002
M3 - Article
C2 - 16769278
AN - SCOPUS:33745044215
SN - 0002-9610
VL - 192
SP - 68
EP - 71
JO - American Journal of Surgery
JF - American Journal of Surgery
IS - 1
ER -